Protagenic Therapeutics (PTIX) and Phytanix Bio said Monday that they have agreed to combine in an all-stock deal.
Shares almost quadrupled as intraday trading volume catapulted to over 80 million from a daily average of about 460,000.
BrainStorm Cell Therapeutics (BCLI) said it has received clearance from the US Food and Drug Administration to launch a phase 3b trial of NurOwn to treat amyotrophic lateral sclerosis.
Shares jumped 18%, with intraday trading volume at over 54 million versus a daily average of roughly 178,000.
Roth Capital raised its price target on Sable Offshore (SOC) to $38 from $26 while maintaining its buy rating.
Shares rose 20% as trading volume surged to more than 5.8 million from a daily average of about 1.6 million.
Price: 11.85, Change: +8.82, Percent Change: +291.22
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。